Anticoagulant interventions in hospitalized patients with COVID-19: A scoping review of randomized controlled trials and call for international collaboration.

Tritschler, Tobias; Mathieu, Marie-Eve; Skeith, Leslie; Rodger, Marc; Middeldorp, Saskia; Brighton, Timothy; Sandset, Per Morten; Kahn, Susan R; Angus, Derek C; Blondon, Marc; Bonten, Marc J; Cattaneo, Marco; Cushman, Mary; Derde, Lennie P G; DeSancho, Maria T; Diehl, Jean-Luc; Goligher, Ewan; Jilma, Bernd; Jüni, Peter; Lawler, Patrick R; ... (2020). Anticoagulant interventions in hospitalized patients with COVID-19: A scoping review of randomized controlled trials and call for international collaboration. Journal of thrombosis and haemostasis, 18(11), pp. 2958-2967. Wiley-Blackwell 10.1111/jth.15094

[img] Text
Tritschler, J Thromb Haemost 2020.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB)
[img]
Preview
Text
ACinCOVID_ScopingReview.pdf - Accepted Version
Available under License Publisher holds Copyright.

Download (524kB) | Preview

INTRODUCTION

Coronavirus disease (COVID-19) is associated with a high incidence of thrombosis and mortality despite standard anticoagulant thromboprophylaxis. There is equipoise regarding the optimal dose of anticoagulant intervention in hospitalized patients with COVID-19 and consequently, immediate answers from high-quality randomized trials are needed.

METHODS

The World Health Organization's International Clinical Trials Registry Platform was searched on June 17, 2020 for randomized controlled trials comparing increased dose to standard dose anticoagulant interventions in hospitalized COVID-19 patients. Two authors independently screened the full records for eligibility and extracted data in duplicate.

RESULTS

A total of 20 trials were included in the review. All trials are open label, 5 trials use an adaptive design, 1 trial uses a factorial design, 2 trials combine multi-arm parallel group and factorial designs in flexible platform trials, and at least 15 trials have multiple study sites. With individual target sample sizes ranging from 30 to 3000 participants, the pooled sample size of all included trials is 12 568 participants. Two trials include only intensive care unit patients, and 10 trials base patient eligibility on elevated D-dimer levels. Therapeutic intensity anticoagulation is evaluated in 14 trials. All-cause mortality is part of the primary outcome in 14 trials.

DISCUSSION

Several trials evaluate different dose regimens of anticoagulant interventions in hospitalized patients with COVID-19. Because these trials compete for sites and study participants, a collaborative effort is needed to complete trials faster, conduct pooled analyses and bring effective interventions to patients more quickly.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of General Internal Medicine (DAIM) > Clinic of General Internal Medicine > Centre of Competence for General Internal Medicine

UniBE Contributor:

Tritschler, Tobias

ISSN:

1538-7836

Publisher:

Wiley-Blackwell

Language:

English

Submitter:

Tobias Tritschler

Date Deposited:

02 Nov 2020 08:39

Last Modified:

05 Dec 2022 15:41

Publisher DOI:

10.1111/jth.15094

PubMed ID:

32888372

Uncontrolled Keywords:

COVID-19 anticoagulant pulmonary embolism research networks thrombosis

BORIS DOI:

10.7892/boris.147682

URI:

https://boris.unibe.ch/id/eprint/147682

Actions (login required)

Edit item Edit item
Provide Feedback